Commentary

You have full text access to this OnlineOpen article

The efficacy for unresectable hepatocellular carcinoma may be improved by transcatheter arterial chemoembolization in combination with a traditional Chinese herbal medicine formula

A retrospective study

  1. Yang Yu MD,
  2. Qingbo Lang MD,
  3. Zhe Chen MD,
  4. Bai Li MD,
  5. Chaoqin Yu MD,
  6. Dezeng Zhu MD,
  7. Xiaofeng Zhai MD,
  8. Changquan Ling MD†,*

Article first published online: 11 AUG 2009

DOI: 10.1002/cncr.24567

Issue

Cancer

Cancer

Volume 115, Issue 22, pages 5132–5138, 15 November 2009

Additional Information

How to Cite

Yu, Y., Lang, Q., Chen, Z., Li, B., Yu, C., Zhu, D., Zhai, X. and Ling, C. (2009), The efficacy for unresectable hepatocellular carcinoma may be improved by transcatheter arterial chemoembolization in combination with a traditional Chinese herbal medicine formula. Cancer, 115: 5132–5138. doi: 10.1002/cncr.24567

Author Information

  1. Department of Traditional Chinese Medicine, Changhai Hospital, Second Military Medical University, Shanghai, China

  1. †

    Fax: (011) 86-21-81871559

*Department of Traditional Chinese Medicine, Changhai Hospital, No. 168 Changhai Road, Shanghai, 200433, China

Publication History

  1. Issue published online: 3 NOV 2009
  2. Article first published online: 11 AUG 2009
  3. Manuscript Accepted: 15 APR 2009
  4. Manuscript Revised: 7 APR 2009
  5. Manuscript Received: 22 DEC 2008
Corrected by:

Communication: Notice of duplicate publication

Vol. 118, Issue 2, 292, Article first published online: 5 JAN 2012

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (158K)

References

  • 1
    Garcia M, Jemal A, Ward EM, et al. Global Cancer Facts & Figures 2007. Atlanta, Ga: American Cancer Society; 2007.
  • 2
    Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol. 2008; 48: S20-S37.
  • 3
    Poon RTP, Fan ST, Tsang FHF, et al. Locoregional therapy for hepatocellular carcinoma: a critical review from the surgeon's perspective. Ann Surg. 2002; 235: 466-486.
  • 4
    Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003; 362: 1907-1917.
  • 5
    Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Lancet. 2002; 359: 1734-1739.
  • 6
    Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 2003; 37: 429-442.
    Direct Link:
  • 7
    Ikai I, Arii S, Kojiro M, et al. Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey. Cancer. 2004; 101: 796-802.
    Direct Link:
  • 8
    Arii S, Yamaoka Y, Futagawa S, et al. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. Hepatology. 2000; 32: 1224-1229.
    Direct Link:
  • 9
    Seong J, Park HC, Han KH, et al. Local radiotherapy for unresectable hepatocellular carcinoma patients who failed with transcatheter arterial chemoembolization. Int J Radiat Oncol Biol Phys. 2000; 47: 1331-1335.
  • 10
    Shim JS, Kim JH, Lee J, Kim SN, Kwon HJ. Anti-angiogenic activity of a homoisoflavanone from Cremastra appendiculata. Planta Med. 2004; 70: 171-173.
  • 11
    Xin HL, Yue XQ, Xu YF, et al. Two new polyoxgenated triterpenoids from actinidia valvata. Helvetica Chima Acta. 2008; 91: 575-580.
    Direct Link:
  • 12
    Liver Cancer Panel of the Chinese Anti-Cancer Association. The criteria for clinical diagnosis of primary liver cancer. Chin J Hepatol. 2001; 9: 324.
  • 13
    Greene FL, Page DL, Fleming ID, et al. eds. American Joint Committee on Cancer Staging Manual. 6th ed. Philadelphia, Pa: Springer; 2002.
  • 14
    Tang ZY, ed. Tang Zhao-you's Hepatocellular Carcinoma: Clinical. Shanghai, China: Shanghai Scientific and Technological Education Publishing House; 2001: 162.
  • 15
    Marelli L, Stigliano R, Triantos C. Treatment outcomes for hepatocellular carcinoma using chemoembolization in combination with other therapies. Cancer Treat Rev. 2006; 32: 594-606.
  • 16
    Buscarini L, Buscarini E, Di Stasi M, et al. Percutaneous radiofrequency thermal ablation combined with transcatheter arterial embolization in the treatment of large hepatocellular carcinoma. Ultraschall Med. 1999; 20: 47-53.
  • 17
    Seki T, Tamai T, Nakagawa T, et al. Combination therapy with transcatheter arterial chemoembolization and percutaneous microwave coagulation therapy for hepatocellular carcinoma. Cancer. 2000; 89: 1245-1251.
    Direct Link:
  • 18
    Yamakado K, Nakatsuka A, Akeboshi M, et al. Combination therapy with radiofrequency ablation and transcatheter chemoembolization for the treatment of hepatocellular carcinoma: short-term recurrences and survival. Oncol Rep. 2004; 11: 105-109.
  • 19
    Veltri A, Moretto P, Doriguzzi A, et al. Radiofrequency thermal ablation (RFA) after transarterial chemoembolization (TACE) as a combined therapy for unresectable non-early hepatocellular carcinoma (HCC). Eur Radiol. 2006; 16: 661-669.
  • 20
    Koda M, Murawaki Y, Mitsuda A. Combination therapy with transcatheter arterial chemoembolization and percutaneous ethanol injection compared with percutaneous ethanol injection alone for patients with small hepatocellular carcinoma: a randomized control study. Cancer. 2001; 92: 1516-1524.
    Direct Link:
  • 21
    Bartolozzi C, Lencioni R, Caramella D. Treatment of large HCC: transcatheter arterial chemoembolization combined with percutaneous ethanol injection versus repeated transcatheter arterial chemoembolization. Radiology. 1995; 197: 812-818.
  • 22
    Akamatsu M, Yoshida H, Obi S. Evaluation of transcatheter arterial embolization prior to percutaneous tumor ablation in patients with hepatocellular carcinoma: a randomized controlled trial. Liver Int. 2004; 24: 625-629.
    Direct Link:
  • 23
    Hatanaka Y, Yamashita Y, Takahashi M, et al. Unresectable hepatocellular carcinoma: analysis of prognostic factors in transcatheter management. Radiology. 1995; 195: 747-752.
  • 24
    Group d'Etude et de Traitment du Carcinome Hepatocellulaire. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med. 1995; 332: 1256-1261.
  • 25
    Savastano S, Miotto D, Casarrubea G, et al. Transcatheter arterial chemoembolization for hepatocellular carcinoma in patients with Child's grade A or B cirrhosis: a multivariate analysis of prognostic factors. J Clin Gastroenterol. 1999; 28: 334-340.
  • 26
    Takayasu K, Arii S, Ikai I, et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology. 2006; 131: 461-469.
  • 27
    Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002; 35: 1164-1171.
    Direct Link:
  • 28
    Villa E, Moles A, Ferretti I, et al. Natural history of inoperable hepatocellular carcinoma: estrogen receptors' status in the tumor is the strongest prognostic factor for survival. Hepatology. 2000; 32: 233-238.
    Direct Link:
View Full Article (HTML) Get PDF (158K)